Several challenges exist in targeting PAX3: 1. Specificity: Ensuring that therapies specifically target cancer cells without affecting normal cells that express PAX3 during development. 2. Resistance: Cancer cells may develop resistance to therapies targeting PAX3, necessitating combination therapies. 3. Delivery: Efficient delivery of gene silencing agents or small molecule inhibitors to tumor cells remains a significant hurdle.
